Daily SPAC Update – February 4, 2025

by | Feb 4, 2025

Evergreen (EVGR) Extension Approved. Inflection Point (IPXX) Deal Deck. Aimfinity (AIMAU) Updates Deal Earnouts. Powerup (PWUP) + AspireBioPharma Deal Vote.

Boardroom Alpha SPAC Resources
Full SPAC Listing
SPAC SEC Filings
Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

Daily SPAC Update

SPAC VOTE RESULTS
EVGR – EVERGREEN CORP * Extend to Aug 11, 2025 * 2,456,657 redeemed

OTHER SPAC NEWS
IPXX – INFLECTION POINT ACQUISITION CORP II * Investor Deck
AIMAU – AIMFINITY INVESTMENT CORP I * Merger Agreement Amendment

MERGER VOTES
PWUP – Powerup Acquisition Corp Aspire BioPharma Inc.

Aspire Biopharma, Inc. is a privately held, early-stage biopharmaceutical technology company founded in 2021. The Company is engaged in the business of developing and marketing a disruptive technology for novel delivery mechanisms for “do no harm” FDA approved drugs, nutraceuticals and supplements. Aspire has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, patient compliance and safety and rapid response and absorption time when required and desired.

SEPARATE WARRANTS/RIGHTS
Feb 06: HENNESSY CAPITAL INVESTMENT CORP VII (HVII)

YESTERDAY’S TOP SPAC GAINERS
11.78% ~ $ 9.87 | GLST – GLOBAL STAR ACQUISITION INC (Announced)
3.14% ~ $ 12.50 | TETE – TECHNOLOGY & TELECOMMUNICATION ACQUISITION CORP (Announced)
1.61% ~ $ 11.99 | MSSA – METAL SKY STAR ACQUISITION CORP (Pre-Deal)
1.46% ~ $ 11.85 | HSPO – HORIZON SPACE ACQUISITION I CORP (Announced)
1.42% ~ $ 11.39 | DIST – DISTOKEN ACQUISITION CORP (Announced)

YESTERDAY’S TOP SPAC LOSERS
-21.57% ~ $ 4.80 | BOWN – BOWEN ACQUISITION CORP (Announced)
-18.86% ~ $ 10.50 | PWUP – POWERUP ACQUISITION CORP (Announced)
-11.52% ~ $ 9.75 | WAVS – WESTERN ACQUISITION VENTURES CORP (Announced)
-7.56% ~ $ 11.00 | PLMJ – PLUM ACQUISITION CORP III (Announced)
-2.58% ~ $ 11.69 | CSLM – CSLM ACQUISITION CORP (Announced)

LATEST SPAC IPO PERFORMANCE
Jan 29 | $ 10.04 | SVCC – Stellar V Capital Corp.
Jan 28 | $ .00 | FGMC – FG Merger II Corp.
Jan 27 | $ 10.02 | DMAA – Drugs Made In America Acquisition Corp.
Jan 21 | $ 10.06 | COLA – Columbus Acquisition Corp
Jan 16 | $ 10.04 | HVII – Hennessy Capital Investment Corp. VII
Jan 14 | $ 10.09 | RIBB – Ribbon Acquisition Corp.
Jan 14 | $ 10.05 | PLMK – Plum Acquisition Corp, IV
Jan 07 | $ 10.06 | CEPO – Cantor Equity Partners I, Inc.

Recent Analysis

Daily SPAC Update – February 12, 2025

Nabors Energy Transition II (NETD) Deal Announced with e2Companies. Atherium (GMFI) Extension Vote. Global Star (GLST) Fixes Trust Mistake. FTAC Emerald (FLDD) Deal Vote Delayed to Feb 13.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.